|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 5/103 | |
| C07K 5/087 | |||
| C07K 5/08 | |||
| A61K 38/06 |
| (11) | Number of the document | 2270026 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10012497.3 |
| Date of filing the European patent application | 2005-08-08 | |
| (97) | Date of publication of the European application | 2011-01-05 |
| (45) | Date of publication and mention of the grant of the patent | 2016-05-18 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 599401 P | 2004-08-06 | US | |
| 610001 P | 2004-09-14 | US | |
| 106879 | 2005-04-14 | US |
| (72) |
Smyth, Mark S., US
Laidig, Guy J., US
|
| (73) |
Onyx Therapeutics, Inc.,
249 E. Grand Avenue, South San Francisco, CA 94080,
US
|
| (54) | Compounds for proteasome enzyme inhibition |
| Compounds for proteasome enzyme inhibition |